AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1629885 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 86
Study 1629885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 86
Study 1629885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day)
Number of subjects: 86
Study 1629885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 6835890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg meptazinol/kg/hr
Number of subjects: 30
Study 6835890 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg pethidine/kg/hr
Number of subjects: 30
Study 6835890 — intervention group
Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 30
Study 6835890 — intervention group
Group type: EXPERIMENTAL
Intervention: meptazinol
Number of subjects: 30
Study 28544170 — intervention group
Group type: EXPERIMENTAL
Intervention: NHEBEF (Nordic hamstring exercises before training)
Number of subjects: 35
Study 28544170 — intervention group
Group type: EXPERIMENTAL
Intervention: NHEAFT (Nordic hamstring exercises after training)
Number of subjects: 35
Study 28544170 — intervention group
Group type: COMPARATOR
Intervention: CON (core stability exercises)
Number of subjects: 35
Study 25944829 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational strategy by community health volunteers (CHVs)
Number of subjects: 231
Study 25944829 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal education program using paid health professionals (FHPs)
Number of subjects: 231
Study 25944829 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 231
Study 25331625 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 (1,000 mg)
Number of subjects: 40
Study 25331625 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-281959 (F2) 70 mg
Number of subjects: 40
Study 25331625 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 (dF) 50 mg
Number of subjects: 40
Study 25331625 — intervention group
Group type: COMPARATOR
Intervention: ACT-281959 (F1) 70 mg
Number of subjects: 40
Study 23526240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac + B vitamins mixture (75 mg sodium diclofenac, 100 mg thiamine, 100 mg pyridoxine, 5 mg cyanocobalamin)
Number of subjects: 48
Study 23526240 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac alone (75 mg sodium diclofenac)
Number of subjects: 48
Study 19663757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeline sulfate
Number of subjects: 750
Study 19663757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 18756970 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 + IL-2
Number of subjects: 50
Study 18756970 — intervention group
Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 50
Study 16814644 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping Cypher sirolimus‐eluting stents (SES)
Number of subjects: 575
Study 16814644 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 575
Study 15247556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 400/100 mg BID + Phenytoin 300 mg QD (days 11-22)
Number of subjects: 24
Study 15247556 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg QD + Lopinavir/ritonavir 400/100 mg BID (days 12-23)
Number of subjects: 24
Study 11243418 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg
Number of subjects: 24
Study 11243418 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan 25 mg
Number of subjects: 24
Study 11243418 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan 50 mg
Number of subjects: 24
Study 11243418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8988349 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of intranasal salmon calcitonin (sCT) 200 IE
Number of subjects: 9
Study 8988349 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration of intranasal salmon calcitonin (sCT) 200 IE
Number of subjects: 9
Study 8988349 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 9
Study 8500919 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of loxapine
Number of subjects: 0
Study 8500919 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of loxapine
Number of subjects: 0
Study 3481316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200mg bid for 6 days
Number of subjects: 7
Study 29423947 — intervention group
Group type: EXPERIMENTAL
Intervention: AXP1275 (50 mg)
Number of subjects: 21
Study 29423947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27100717 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Number of subjects: 104
Study 27100717 — intervention group
Group type: COMPARATOR
Intervention: Hot Snare Resection
Number of subjects: 104
Study 27100717 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR) for polyps >20mm
Number of subjects: 104
Study 27100717 — intervention group
Group type: COMPARATOR
Intervention: Hot Snare Resection for polyps >20mm
Number of subjects: 104
Study 27100717 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR) for polyps <19mm
Number of subjects: 104
Study 27100717 — intervention group
Group type: COMPARATOR
Intervention: Hot Snare Resection for polyps <14mm
Number of subjects: 104
Study 25919118 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 25919118 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 30
Study 23589560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus carboplatin
Number of subjects: 191
Study 23589560 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin
Number of subjects: 191
Study 19713947 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss diet (WL) with caloric restriction of 500 kcal/d
Number of subjects: 34
Study 19713947 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet plus resistance training (WL+RT) with caloric restriction of 500 kcal/d and 16-week supervised whole body PRT (2 sessions/week)
Number of subjects: 34
Study 19713947 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 34
Study 18439201 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of alcohol mixed with energy drinks (AmED)
Number of subjects: 4271
Study 16770694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (group or individual)
Number of subjects: 466
Study 12814414 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term pre-operative cessation of smoking, counselling and nicotine replacement therapy
Number of subjects: 60
Study 12814414 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of daily smoking habits
Number of subjects: 60
Study 10403266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day)
Number of subjects: 126
Study 10403266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 10403266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 126
Study 7587218 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0
Study 7587218 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin therapy
Number of subjects: 0
Study 7587218 — intervention group
Group type: EXPERIMENTAL
Intervention: Various estrogen and estrogen/progestin regimens
Number of subjects: 0
Study 7587218 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and estrogen/progestin therapy
Number of subjects: 0
Study 2405897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 45
Study 2405897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 45
Study 2405897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.0%
Number of subjects: 45
Study 7441009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin with gentamicin
Number of subjects: 175
Study 7441009 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol with gentamicin
Number of subjects: 175
Study 7441009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin with gentamicin
Number of subjects: 175
Study 7441009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 175
Study 7441009 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 175
Study 7441009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 175
Study 30994410 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based health coaching (INT group) with weekly videoconferencing for health coaching and monthly medical monitoring.
Number of subjects: 25
Study 30994410 — intervention group
Group type: COMPARATOR
Intervention: Self-guided (CON group) without weekly health coaching.
Number of subjects: 25
Study 30082170 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg once daily) combined with oral etoposide (50 mg once daily on days 1-14 of a 21-day cycle)
Number of subjects: 35
Study 30082170 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with oral etoposide
Number of subjects: 35
Study 26920573 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 30
Study 26920573 — intervention group
Group type: COMPARATOR
Intervention: Informational pamphlet (IP)
Number of subjects: 30
Study 24636462 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 50mg u.i.d.
Number of subjects: 62
Study 24636462 — intervention group
Group type: COMPARATOR
Intervention: Melatonin 10mg u.i.d.
Number of subjects: 62
Study 24636462 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from melatonin to agomelatine
Number of subjects: 62
Study 23867888 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralaterally controlled neuromuscular electrical stimulation (CCNMES)
Number of subjects: 26
Study 23867888 — intervention group
Group type: COMPARATOR
Intervention: Cyclic neuromuscular electrical stimulation (NMES)
Number of subjects: 26
Study 23867888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CCNMES and cyclic NMES combined with gait training
Number of subjects: 26
Study 20838215 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg/d before bedtime)
Number of subjects: 13
Study 20838215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27950535 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (E) 150 mg orally QD plus sulindac (S) 150 mg orally BID (Arm A)
Number of subjects: 85
Study 27950535 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (E) 150 mg QD (Arm B)
Number of subjects: 85
Study 27950535 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD (Arm C)
Number of subjects: 85
Study 27950535 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Erlotinib (E) 150 mg QD for 2 years after postoperative chemoradiotherapy
Number of subjects: 85
Study 16368840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group (lidocaine 1.5% with 2 mL of dexamethasone 8 mg)
Number of subjects: 60
Study 16368840 — intervention group
Group type: COMPARATOR
Intervention: Control group (lidocaine 1.5% with 2 mL of isotonic saline chloride)
Number of subjects: 60
Study 14551182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg per day
Number of subjects: 40
Study 14551182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone titrated to a daily dose of 400 mg
Number of subjects: 40
Study 14551182 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days
Number of subjects: 40
Study 14551182 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine titrated to a daily dose of 200 mg
Number of subjects: 40
Study 10319663 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion counseling from trained professional home care nurses
Number of subjects: 84
Study 10319663 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (Control)
Number of subjects: 84
Study 8731122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intussuscepted ileal nipple valve
Number of subjects: 30
Study 8731122 — intervention group
Group type: COMPARATOR
Intervention: Stapled ileal ('Lundiana') outlet
Number of subjects: 30
Study 1777912 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast agent
Number of subjects: 12
Study 1777912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast agent
Number of subjects: 12
Study 7036376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicitropeptide powder
Number of subjects: 50
Study 7036376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3882108 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium nitroprusside (SNP)
Number of subjects: 20
Study 3882108 — intervention group
Group type: COMPARATOR
Intervention: trimetaphan (TMP)
Number of subjects: 20
Study 31357259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Group (HIG)
Number of subjects: 62
Study 31357259 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Group (LIG)
Number of subjects: 62
Study 29908775 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (measured by HOMA-IR)
Number of subjects: 738
Study 27089205 — intervention group
Group type: EXPERIMENTAL
Intervention: TV003
Number of subjects: 41
Study 27089205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25424120 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX)
Number of subjects: 340
Study 25424120 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (CapeOX)
Number of subjects: 340
Study 22945622 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 36
Study 22945622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Number of subjects: 36
Study 19707823 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg (group O4)
Number of subjects: 120
Study 19707823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg (group O8)
Number of subjects: 120
Study 19707823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (group R)
Number of subjects: 120
Study 18822983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy He-Ne laser radiation at acupoints (CV 22, ST 9, CV 14, BL 12) for 5 days
Number of subjects: 255
Study 18822983 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Amantadine tablets for 5 days
Number of subjects: 255
Study 15702134 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose finasteride
Number of subjects: 27
Study 15702134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11791151 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 days per week, 45 min per session, at 65% of heart rate reserve
Number of subjects: 27
Study 11791151 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=9)
Number of subjects: 27
Study 10404019 — intervention group
Group type: COMPARATOR
Intervention: MK-677 10 mg for 2 weeks
Number of subjects: 187
Study 10404019 — intervention group
Group type: COMPARATOR
Intervention: MK-677 25 mg for 2 weeks
Number of subjects: 187
Study 10404019 — intervention group
Group type: COMPARATOR
Intervention: MK-677 25 mg daily for 2 weeks followed by 50 mg daily for 2 weeks
Number of subjects: 187
Study 10404019 — intervention group
Group type: COMPARATOR
Intervention: MK-677 (all groups combined) for 9 weeks
Number of subjects: 187
Study 8567514 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+MCT trial (15% CHO solution + 29 g MCT suspension)
Number of subjects: 8
Study 8567514 — intervention group
Group type: EXPERIMENTAL
Intervention: HCHO+MCT trial (high CHO (HCHO) 214 g + 29 g MCT suspension)
Number of subjects: 8
Study 8567514 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT trial (29 g MCT solution)
Number of subjects: 8
Study 1963734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive coping, years of problem drinking
Number of subjects: 39
Study 1963734 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aftercare attendance
Number of subjects: 39
Study 1963734 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous hospitalizations
Number of subjects: 39
Study 1963734 — intervention group
Group type: COMPARATOR
Intervention: Demographics (age, marital status)
Number of subjects: 39
Study 6993630 — intervention group
Group type: EXPERIMENTAL
Intervention: Frostig Program for the Development of Visual Perception
Number of subjects: 36
Study 6993630 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention-placebo)
Number of subjects: 36
Study 31260124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast 8% liposomal gel
Number of subjects: 40
Study 31260124 — intervention group
Group type: COMPARATOR
Intervention: Water-based placebo
Number of subjects: 40
Study 31091343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care addressing patients' sleep
Number of subjects: 53
Study 31091343 — intervention group
Group type: COMPARATOR
Intervention: Current training addressing sleep during hospital stay
Number of subjects: 53
Study 31091343 — intervention group
Group type: COMPARATOR
Intervention: Policy documents regarding sleep management
Number of subjects: 53
Study 28872752 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months supervised exercise followed by a 6-month home-based maintenance programme
Number of subjects: 100
Study 28872752 — intervention group
Group type: COMPARATOR
Intervention: Printed physical activity educational material for 12 months
Number of subjects: 100
Study 27769191 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Learning and Action (PLA)
Number of subjects: 8880
Study 27769191 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA plus food (10 kg of fortified sweetened wheat-soya Super Cereal per month)
Number of subjects: 8880
Study 27769191 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA plus cash (NPR 750 or US$7 per month)
Number of subjects: 8880
Study 27769191 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 8880
Study 27769191 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (PLA, PLA plus food, PLA plus cash, standard care)
Number of subjects: 8880
Study 25062747 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive-behavioural therapy (iCBT)
Number of subjects: 212
Study 25062747 — intervention group
Group type: COMPARATOR
Intervention: internet-based therapist-assisted progressive relaxation training (iPRT)
Number of subjects: 212
Study 22158066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed hypertension medications upon awakening
Number of subjects: 607
Study 22158066 — intervention group
Group type: COMPARATOR
Intervention: Ingesting ≥1 hypertension medication at bedtime
Number of subjects: 607
Study 20120778 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg/day)
Number of subjects: 18
Study 20120778 — intervention group
Group type: COMPARATOR
Intervention: Losartan (200 mg/day)
Number of subjects: 18
Study 17473072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg daily
Number of subjects: 16
Study 17473072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15215284 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of >=5% in any month
Number of subjects: 900
Study 15215284 — intervention group
Group type: EXPERIMENTAL
Intervention: Average random fluctuation in weight
Number of subjects: 900
Study 15215284 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly weight fluctuations
Number of subjects: 900
Study 11215231 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml added to 1% propofol 20 ml (Group L)
Number of subjects: 34
Study 11215231 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 ml added to 1% propofol 20 ml (Group S)
Number of subjects: 34
Study 9099660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside presentations
Number of subjects: 182
Study 9099660 — intervention group
Group type: COMPARATOR
Intervention: Conference-room presentations
Number of subjects: 182
Study 8157036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg b.d. for 12 weeks and fluvastatin 20 mg AM + 40 mg PM for an additional 12 weeks (Group A)
Number of subjects: 52
Study 8157036 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 40 mg qPM during the entire study (Group B)
Number of subjects: 52
Study 8157036 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group A (60 mg) vs Group B (40 mg qPM)
Number of subjects: 52
Study 3093221 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg enoxacin
Number of subjects: 123
Study 3093221 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin
Number of subjects: 123
Study 3093221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 31753271 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light warning label
Number of subjects: 10412
Study 31753271 — intervention group
Group type: EXPERIMENTAL
Intervention: Red stop sign warning label
Number of subjects: 10412
Study 31753271 — intervention group
Group type: COMPARATOR
Intervention: Sodium warning labels (various designs)
Number of subjects: 10412
Study 28264693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored programme for implementing recommendations for multimorbid patients with polypharmacy; includes structured medication counselling, medication lists, and medication reviews.
Number of subjects: 0
Study 28264693 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 25669315 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 19
Study 25669315 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 19
Study 23022750 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the left posterior middle frontal gyrus (EEG electrode location F3) with an intensity of 110% of the individual resting motor threshold (RMT) for 15 sessions
Number of subjects: 47